Mineralys Therapeutics, Inc.
MLYS
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comor…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$370M
▲ +13.0% YoY
Op. Margin
–
ROIC
-52.64%
▲ +38.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$153M
▲ +14.4% YoY
Op. Cash Flow (TTM)
-$153M
▲ +14.4% YoY
Net Debt
-$101M
Net Cash Position
Cash & Equiv.
$101M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with MLYS
Held by ETFs
MLYS is in 37 US ETFs. The largest of them, with MLYS's weight in each:
Mineralys Therapeutics (MLYS) in two numbers
Questions about Mineralys Therapeutics
Does Mineralys Therapeutics (MLYS) pay a dividend?
No. Mineralys Therapeutics (MLYS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 29 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in MLYS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MLYS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.